Piedmont Investment Advisors Inc. increased its position in shares of Zoetis Inc (NYSE:ZTS) by 1.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 42,860 shares of the company’s stock after acquiring an additional 672 shares during the quarter. Piedmont Investment Advisors Inc.’s holdings in Zoetis were worth $4,315,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Berman Capital Advisors LLC boosted its position in Zoetis by 46.8% during the first quarter. Berman Capital Advisors LLC now owns 480 shares of the company’s stock worth $48,000 after acquiring an additional 153 shares during the last quarter. Becker Capital Management Inc. boosted its position in Zoetis by 9.0% during the first quarter. Becker Capital Management Inc. now owns 3,270 shares of the company’s stock worth $329,000 after acquiring an additional 270 shares during the last quarter. Freestone Capital Holdings LLC boosted its position in Zoetis by 88.3% during the first quarter. Freestone Capital Holdings LLC now owns 13,457 shares of the company’s stock worth $1,355,000 after acquiring an additional 6,309 shares during the last quarter. Hanseatic Management Services Inc. boosted its position in Zoetis by 19.6% during the first quarter. Hanseatic Management Services Inc. now owns 1,821 shares of the company’s stock worth $183,000 after acquiring an additional 299 shares during the last quarter. Finally, Rothschild & Co. Asset Management US Inc. boosted its holdings in shares of Zoetis by 9.4% in the 1st quarter. Rothschild & Co. Asset Management US Inc. now owns 4,748 shares of the company’s stock valued at $478,000 after purchasing an additional 407 shares during the last quarter. Hedge funds and other institutional investors own 90.95% of the company’s stock.
In other news, CFO Glenn David sold 8,191 shares of the firm’s stock in a transaction on Friday, May 17th. The shares were sold at an average price of $102.22, for a total value of $837,284.02. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Juan Ramon Alaix sold 312,109 shares of the firm’s stock in a transaction on Thursday, February 28th. The shares were sold at an average price of $94.06, for a total transaction of $29,356,972.54. The disclosure for this sale can be found here. In the last three months, insiders sold 447,975 shares of company stock worth $42,728,902. Insiders own 0.29% of the company’s stock.
Shares of ZTS opened at $102.89 on Friday. The firm has a market capitalization of $49.27 billion, a price-to-earnings ratio of 32.87, a P/E/G ratio of 2.56 and a beta of 0.91. Zoetis Inc has a fifty-two week low of $78.90 and a fifty-two week high of $103.97. The company has a current ratio of 4.05, a quick ratio of 2.79 and a debt-to-equity ratio of 2.84.
Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, May 2nd. The company reported $0.88 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.79 by $0.09. Zoetis had a net margin of 23.47% and a return on equity of 73.66%. The company had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.45 billion. During the same quarter last year, the business earned $0.75 EPS. Zoetis’s revenue for the quarter was up 6.5% on a year-over-year basis. Sell-side analysts forecast that Zoetis Inc will post 3.48 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 19th will be paid a $0.164 dividend. This represents a $0.66 dividend on an annualized basis and a dividend yield of 0.64%. The ex-dividend date of this dividend is Thursday, July 18th. Zoetis’s dividend payout ratio is presently 21.09%.
A number of equities analysts have weighed in on ZTS shares. Zacks Investment Research lowered shares of Zoetis from a “buy” rating to a “hold” rating in a report on Monday, May 6th. Gabelli lowered shares of Zoetis from a “buy” rating to a “hold” rating and set a $108.00 price target on the stock. in a report on Thursday, May 2nd. They noted that the move was a valuation call. Credit Suisse Group lifted their price target on shares of Zoetis from $102.00 to $112.00 and gave the company an “outperform” rating in a report on Tuesday, April 2nd. Guggenheim started coverage on shares of Zoetis in a report on Thursday. They issued a “buy” rating and a $114.00 price target on the stock. Finally, SunTrust Banks started coverage on shares of Zoetis in a report on Tuesday, March 19th. They issued a “hold” rating and a $100.00 price target on the stock. Six research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Zoetis currently has an average rating of “Buy” and a consensus price target of $103.93.
TRADEMARK VIOLATION NOTICE: “Piedmont Investment Advisors Inc. Has $4.32 Million Position in Zoetis Inc (ZTS)” was originally reported by Highlight Press and is owned by of Highlight Press. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://highlightpress.com/2019/05/24/piedmont-investment-advisors-inc-has-4-32-million-position-in-zoetis-inc-zts.html.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Featured Article: How to calculate the intrinsic value of a stock
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.